Supplementary methods
Disease response analysis. Shown are ratios of quantitative PCR expression levels of selected miRNAs from patients before (baseline) and during natalizumab therapy. A) Comparison of patients that improved in EDSS (n=6) and that were stable or deteriorated (n=11). B) Comparison of patients that improved or were stable (n=15) and that deteriorated (n=2 Magnetic bead isolated mouse CD4 + cells were incubated with anti-CD3-antibody (1µg/ml), IL-6 (20ng/ml) and TGF-beta (2ng/ml) for 4 days in the presence of irradiated APC. Analysis was performed using BD Leukocyte Activation Cocktail, intracellular staining using BD Cytofix/Cytoperm buffers (Becton Dickinson) and subsequent FACS analysis. Pooled data from 4 experiments (each n=5/per group). Non-PML natalizumab treated PML (natalizumab-associated) miRNA levels in PBMC from natalizumab treated patients (n=9, left bar) were compared to two PBMC samples from patients with natalizumab-associated PML (each patient one bar). Due to small sample size statistical tests were not performed.
C
PBMC were isolated using a ficoll gradient and CD4 + T cells were sorted with magnetic beads (n=9). miRNA expression was measured in freshly isolated CD4 + cells ("fresh), CD4 + cells that were activated by plate-bound anti-CD3-antibody and soluble anti-CD28-antibody without further cytokines, (termed "Th0") and with IL-1 (10ng/ml), IL-6 (10ng/ml), IL23 (10ng/ml) and TGB-beta (5ng/ml), termed "Th17") by qPCR. Significance was calculated using t test.
PBMC were isolated using a ficoll gradient and CD4 + T cells were sorted with magnetic beads (n=9). miRNA expression was measured in CD4 + cells and CD4-PBMC by qPCR. Significance was calculated using t test. 
